Post-earnings recap
Reported
Thu, May 5, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
Twist Bioscience's earnings report shows a wider-than-expected loss per share, which contributed to a significant drop in stock price. The lack of revenue data and guidance may have heightened investor concerns. The stock's decline reflects uncertainty about the company's future performance amid market challenges.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.13 | N/A | +10.10% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed caution regarding current market conditions. They highlighted the importance of adapting to ongoing challenges.
Management acknowledged ongoing challenges in the market.
They emphasized the need for strategic adjustments moving forward.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—